Inventor

GRAHAM KENNETH S

US11 patents

⚠️ This page may combine multiple inventors who share the name “GRAHAM KENNETH S”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

REGENERON PHARMA

7 patents

US7807164B2Oct 5, 2010

Lyophilized VEGF antagonist formulations for intravitreal administration

REGENERON PHARMA83 citations98

US10072086B2Sep 11, 2018

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

REGENERON PHARMA12 citations91

US11103552B2Aug 31, 2021

High concentration VEGF receptor fusion protein containing formulations

REGENERON PHARMA8 citations79

US11098127B2Aug 24, 2021

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

REGENERON PHARMA1 citations72

US12077593B2Sep 3, 2024

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

REGENERON PHARMA0 citations61

US12168036B2Dec 17, 2024

Methods for treating angiogenic eye disorders with high doses of VEGF receptor fusion proteins

REGENERON PHARMA0 citations58

US11071780B2Jul 27, 2021

Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab

REGENERON PHARMA0 citations58

FURFINE ERIC

1 patent

US8092803B2Jan 10, 2012

VEGF antagonist formulations for intravitreal administration

FURFINE ERIC136 citations98

DIX DANIEL B

1 patent

US9173880B2Nov 3, 2015

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

DIX DANIEL B96 citations97

REGENERON PHARMACUTICALS INC

1 patent

US7608261B2Oct 27, 2009

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACUTICALS INC131 citations96

HOPE CITY

1 patent

US5986071ANov 16, 1999

Method for C-terminal degradation of peptides and proteins

HOPE CITY1 citations51